Online inquiry

IVTScrip™ mRNA-Anti-CD3E&SSTR2, XmAb-18087(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15833MR)

This product GTTS-WQ15833MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD3E&SSTR2 gene. The antibody can be applied in Cancer research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_000733.4; NM_001050.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 6752
UniProt ID P07766; P30874
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&SSTR2, XmAb-18087(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ15833MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13134MR IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PF-04360365
GTTS-WQ8608MR IVTScrip™ mRNA-Anti-CD33, HuM195(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA HuM195
GTTS-WQ3432MR IVTScrip™ mRNA-Anti-HGF, AV-299(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA AV-299
GTTS-WQ13504MR IVTScrip™ mRNA-Anti-SNCA, PRX002(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PRX002
GTTS-WQ3621MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1179470(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BAY 1179470
GTTS-WQ14950MR IVTScrip™ mRNA-Anti-PDCD1, SHR-1210(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SHR-1210
GTTS-WQ7942MR IVTScrip™ mRNA-Anti-ICOS, GSK-3359609(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GSK-3359609
GTTS-WQ13141MR IVTScrip™ mRNA-Anti-NGF, PF-04383119(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PF-04383119
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW